Veradermics (MANE) Change in Accured Expenses (2025 - 2026)

Veradermics (MANE) reported Change in Accured Expenses of -$8000.0 for Q1 2026, down 14.29% on a YoY basis from -$9333.3 in Q1 2025, and down 14.29% quarter-over-quarter from -$7000.0 in Q1 2025.

Veradermics (MANE) Change in Accured Expenses (2025 - 2026) Analysis & Trends

Veradermics has reported Change in Accured Expenses for 2 years, with the latest figure at -$8000.0 in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - 931,000.00
7 Psyence Biomedical 212.16 Bn 212.16 Bn - 644,700.00
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 70.50 Mn
9 Abivax 91.96 Bn 91.96 Bn - -
10 Veradermics 2.13 Bn 2.13 Bn - -8,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 -8,000.00
Mar 31, 2026 -8,000.00
Mar 31, 2025 -7,000.00
Mar 31, 2025 -7,000.00